Sana Biotechnology (SANA) Corporate presentation summary

Addressing unmet needs in type 1 diabetes

• Approximately 10 million people globally live with type 1 diabetes, facing significant disease burden and reduced life expectancy despite current therapies.

• Insulin replacement is not curative, and patients seek alternatives that address both daily management and long-term complications.

Hypoimmune technology and clinical validation

• Hypoimmune gene edits enable allogeneic islet cell transplantation without immunosuppression, overcoming a major barrier in cell therapy.

• Clinical trial data show transplanted HIP islet cells survive and function for at least one year in a T1D patient, with no immune response or therapy-related adverse events.

• Imaging and biomarker data confirm graft survival and endogenous insulin production.

SC451 program and development milestones

• SC451 is a stem cell-derived, hypoimmune islet cell therapy for T1D, aiming for a single treatment with durable glucose control and no immunosuppression.

• Progress in 2025 included manufacturing scale-up, regulatory engagement, and clinical planning.

• IND filing and Phase 1 trial initiation are targeted for 2026, with clear success metrics: safety, cell survival, and insulin independence.